{"id":"pantoprazole-low-dose","safety":{"commonSideEffects":[{"rate":"9-13","effect":"Headache"},{"rate":"5-8","effect":"Diarrhea"},{"rate":"4-7","effect":"Nausea"},{"rate":"3-5","effect":"Abdominal pain"},{"rate":"3-4","effect":"Flatulence"}]},"_chembl":{"chemblId":"CHEMBL1502","moleculeType":"Small molecule","molecularWeight":"383.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pantoprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This reduces intragastric acidity and is used to treat acid-related gastrointestinal disorders. The low-dose formulation maintains therapeutic efficacy while potentially reducing systemic exposure and associated risks.","oneSentence":"Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:27.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Acid-related gastrointestinal disorders"}]},"trialDetails":[{"nctId":"NCT00713947","phase":"PHASE4","title":"Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-04","conditions":"Positive Helicobacter Pylori Serology, Coronary Thrombosis, Supra-aortic Artery Thrombosis","enrollment":""},{"nctId":"NCT03814421","phase":"NA","title":"Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding","status":"UNKNOWN","sponsor":"Samsung Changwon Hospital","startDate":"2016-04-15","conditions":"Peptic Ulcer Hemorrhage, Peptic Ulcer, Acute With Hemorrhage, Peptic Ulcer","enrollment":200},{"nctId":"NCT04217512","phase":"PHASE3","title":"Pantoprazole in Cisplatin Nephrotoxicity","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2019-05-01","conditions":"Oncology","enrollment":60},{"nctId":"NCT03925818","phase":"NA","title":"Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication","status":"TERMINATED","sponsor":"Università degli Studi di Sassari","startDate":"2017-08-29","conditions":"Helicobacter Pylori Infection","enrollment":99},{"nctId":"NCT00744419","phase":"PHASE1","title":"Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2009-05","conditions":"Gastroesophageal Reflux","enrollment":24},{"nctId":"NCT01447498","phase":"NA","title":"Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2011-04","conditions":"Coronary Occlusion/Thrombosis, Peptic Ulcer Hemorrhage","enrollment":2024},{"nctId":"NCT02170740","phase":"PHASE1","title":"Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT00300755","phase":"PHASE3","title":"Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-05","conditions":"Gastroesophageal Reflux","enrollment":60},{"nctId":"NCT00362609","phase":"PHASE3","title":"Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-07","conditions":"Gastroesophageal Reflux","enrollment":59},{"nctId":"NCT00259012","phase":"PHASE3","title":"Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-11","conditions":"Gastroesophageal Reflux","enrollment":67},{"nctId":"NCT00868296","phase":"PHASE3","title":"Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-03","conditions":"Gastroesophageal Reflux","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["zurcal"],"phase":"phase_3","status":"active","brandName":"Pantoprazole low dose","genericName":"Pantoprazole low dose","companyName":"Sherief Abd-Elsalam","companyId":"sherief-abd-elsalam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Acid-related gastrointestinal disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}